Danazol therapy in hormone-sensitive mammary carcinoma
article
OA: bronze
CC0
⤵ 6 in-corpus citations
AI-generated summary
Danazol therapy induced mammary carcinoma regression in rats and significantly inhibited carcinogenesis when administered after DMBA exposure.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
The effect of Danazol, a synthetic gonadotropin inhibitor, on two groups of Sprague-Dawley rats with dimethylbenze (a) anthracine (DMBA) induced mammary carcinoma was studied. Twenty-four (83%) of 29 control animals developed mammary tumors. Forty-four rats in one treatment group received Danazol after tumor reached 0.5 cm in diameter. Twenty-nine (66%) demonstrated tumor regression (p less than 0.005) and in 16 (36%) tumor disappeared (p less than 0.005). In a second treatment group (given Danazol daily after administration of DMBA), only seven of 50 rats (14%) developed palpable mammary carcinoma (p less than 0.0005). Danazol therapy resulted in regression of established mammary carcinoma in rats, and produced a striking inhibition of carcinogenesis in those animals treated from the time DMBA was administered. Danazol is clinically safe; studies using it in the treatment of breast cancer in women who are candidates for hormonal ablative therapy seem warranted.
My notes (saved in your browser only)
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (14)
- Danazol—a Synthetic Steroid Derivative with Interesting Physiologic Properties via openalex
- Hormonal changes associated with Danazol therapy. via openalex
- Pituitary and Testicular Function Studies. I. Experience with a New Gonadal Inhibitor, 17α-Pregn-4-en-20-yno-(2,3-d) isoxazol-17-ol (Danazol)<sup>1</sup> via openalex
- Pituitary Gonadotropin Inhibitory Activity of Danazol via openalex
- Treatment of endometriosis with Danazol via openalex
- doi:10.1126/science.156.3778.1050 via openalex
- doi:10.1126/science.137.3526.257 via openalex
- doi:10.1001/archsurg.1972.04180020086017 via openalex
- doi:10.1016/s0022-4804(64)80021-4 via openalex
- doi:10.1002/path.1700850210 via openalex
- doi:10.1001/jama.1975.03260240079042 via openalex
- doi:10.1084/jem.109.1.25 via openalex
- doi:10.1095/biolreprod10.4.438 via openalex
- doi:10.1056/nejm197611112952005 via openalex
Cited by (5)
- The effect of danazol on tumour control and weight loss in patients on tamoxifen therapy for advanced breast cancer: A randomised double-blind placebo controlled trial 1993
- Suppression of the development of uterine adenomyosis by danazol treatment in mice 1992
- Danazol induced hypercalcemia in breast cancer 1984
- The effect of Danazol on the pituitary function, thyroid function, and mastodynia 1980
- Danazol for benign breast disease 1980
Source provenance
- openalex
- last seen: 2026-05-10T11:43:40.389167+00:00
License: CC0
· commercial use OK